Top Page
Holista Colltech Limited
(Sydney:HCT)
Holista Colltech Limited (HCT) vs. iShares MSCI Australia ETF (EWA)
Holista Colltech Limited Business Overview & Revenue Model
Holista Colltech Limited Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 5.60M | 5.95M | 8.24M | 8.02M | 7.11M | Gross Profit |
| 2.80M | 2.62M | 1.01M | 1.31M | 873.15K | EBIT |
| 884.53K | -2.26M | -1.42M | -1.25M | -4.54M | EBITDA |
| 376.60K | -4.52M | -1.02M | -957.40K | -5.30M | Net Income Common Stockholders |
| -84.21K | -4.81M | -1.45M | -1.26M | -5.48M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 21.72K | 59.77K | 117.53K | 1.21M | 2.73M | Total Assets |
| 3.34M | 3.35M | 5.52M | 6.93M | 8.05M | Total Debt |
| 1.77M | 1.57M | 1.22M | 890.32K | 942.70K | Net Debt |
| 1.74M | 1.51M | 1.10M | -322.77K | -1.78M | Total Liabilities |
| 6.71M | 6.74M | 3.96M | 3.95M | 3.41M | Stockholders Equity |
| -1.73M | -1.97M | 2.83M | 4.10M | 5.42M |
| Cash Flow | Free Cash Flow | |||
| -1.02M | -411.67K | -1.19M | -1.72M | -3.90M | Operating Cash Flow |
| -973.46K | -407.12K | -1.11M | -1.68M | -3.87M | Investing Cash Flow |
| 632.44K | -46.70K | -105.69K | 50.35K | -80.75K | Financing Cash Flow |
| 116.24K | 418.42K | 120.85K | 109.49K | 6.58M |
Holista Colltech Limited Technical Analysis
Holista Colltech Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$696.11M | ― | -56.99% | ― | 10.76% | -195.89% | |
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
44 Neutral | $66.72M | ― | -55.44% | ― | ― | 49.25% | |
43 Neutral | AU$14.29M | ― | ― | -5.86% | 98.26% | ||
43 Neutral | $44.06M | ― | -75.39% | ― | ― | 44.29% | |
41 Neutral | AU$3.20M | ― | -163.00% | ― | ― | 9.19% |
Holista Colltech Limited Corporate Events
Holista Colltech Limited has announced a strategic shift in its ovine collagen business, including the closure of its Collie facility and plans to establish a new modular production model. The company is focusing on developing nano-collagen for advanced medical applications, such as wound healing and bio-ink for organ printing, and has partnered with Akrivis Health Care to enhance its nano-collagen capabilities. Holista is also working on securing intellectual property rights and expanding its market presence through a proposed license agreement with Regenerex Pharma Inc. for international markets.
Holista Colltech Limited has announced the appointment of Yuen Keong Yee as a director, effective May 14, 2025. This appointment is part of the company’s ongoing efforts to strengthen its leadership team, although the new director currently holds no securities in the company. The announcement is expected to have implications for the company’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations.
Holista Colltech Limited has announced the appointment of Mr. Robert Gemelli and Mr. Sam Yee as Independent Non-Executive Directors, following the resignations of Mr. David Deloub and Ms. Loren King. This strategic change in leadership is expected to bring valuable expertise in biotech commercialization and capital markets, aiding the company in advancing its pipeline and focusing on corporate recovery. The new directors’ diverse backgrounds in various industries are anticipated to strengthen Holista’s board and support its mission to deliver sustainable, science-backed health and wellness solutions.
Holista Colltech Limited has responded to a price query from ASX, confirming that it is not aware of any undisclosed information that could explain recent trading activity in its securities. The company assures compliance with ASX Listing Rules and confirms that its board has authorized the responses provided.
Holista Colltech Limited has announced its Annual General Meeting scheduled for May 29, 2025, at Stantons International in West Perth. The meeting will cover the financial statements and reports for the year ending December 31, 2024, and include several resolutions such as the adoption of the remuneration report, election and re-election of directors, and ratification of prior securities issues. These resolutions are significant for the company’s governance and financial structuring, impacting shareholder interests and the company’s strategic direction.
Holista Colltech Limited has successfully resolved its regulatory issues with ASIC by completing a $900K penalty payment. The company raised $1.53 million through convertible notes to settle this penalty and support working capital. Despite facing increased manufacturing costs and cash flow challenges, Holista recorded $1.9 million in customer receipts and $1.8 million in group sales, largely driven by its Dietary Supplements Division. The company is now focused on corporate recovery, stabilizing operations, and strengthening its financial position.
Holista Colltech Limited has announced an update regarding the conversion of unquoted equity securities, specifically adjusting the amount of converting notes. This update reflects the company’s ongoing financial management and could have implications for its capital structure and investor relations.
Holista Colltech Limited has appointed Mr. Lai Kwok Kin as the new Independent, Non-Executive Chair of the Board. Mr. Lai, who has been an independent Non-Executive Director since March 2024, brings expertise in investor relations and corporate strategy. His appointment follows the resignations of the previous Chair, Mr. David Deloub, and Director, Ms. Loren King. This leadership change is seen as a strategic move to strengthen Holista’s governance and drive sustainable growth.
Holista Colltech Limited has announced the issuance of unquoted equity securities, specifically converting notes, totaling 1,105,262 units. These securities are part of previously announced transactions and are not intended to be quoted on the ASX, indicating a strategic move by the company to manage its equity structure and potentially raise capital.
Holista Colltech Limited announced a late filing of an Initial Director’s Interest Notice for newly appointed director Gregory Pilant, due to an administrative oversight. The company reassures stakeholders that it maintains adequate disclosure procedures and that this incident was an isolated oversight, not indicative of systemic issues.
Holista Colltech Limited announced the resignation of Non-Executive Chair David Deloub and Non-Executive Director Loren King, who have provided four weeks’ notice for personal reasons. The company plans to appoint new directors within this period. This change in leadership comes as Holista continues its mission to innovate in the biotech industry, focusing on natural health solutions and advanced collagen technologies, potentially impacting its strategic direction and stakeholder interests.
Holista Colltech Limited, a company listed on the Australian Securities Exchange, has announced the reinstatement of its securities to trading. This follows the submission of its Annual Report and Appendix 4G for the financial year ending December 31, 2024. The lifting of the suspension is set to take place from the commencement of trading on April 2, 2025, indicating a return to normal operations and potentially restoring investor confidence.
Holista Colltech Limited has released its corporate governance statement for the financial year ending December 31, 2024. The statement, approved by the board and current as of March 31, 2025, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations. The governance disclosures are detailed in the company’s annual report, and the statement serves as a verification tool to confirm compliance with ASX listing rules. This announcement reflects Holista Colltech’s commitment to transparency and accountability in its corporate governance practices, potentially strengthening its position in the market and ensuring stakeholders of its robust management oversight.
Holista Colltech Limited has announced changes in its board of directors, with new appointments including Mr. Leong Man Loong as Executive Director and Interim CEO, and Mr. Gregory Pilant as Non-Executive Director. These changes are expected to impact the company’s strategic direction and governance, potentially influencing its market positioning and stakeholder confidence.
Holista Colltech Ltd has initiated legal proceedings against The ProImmune Company, LLC and its director, Albert Crum, in the Supreme Court of Western Australia. The proceedings seek damages and an injunction related to alleged false representations by ProImmune that led to distribution agreements and a US judgment against Holista. This legal action has delayed the preparation of Holista’s annual accounts for 2024, which are now being lodged.
Holista Colltech Limited has appointed Gregory Pilant as a Non-Executive Director to its board, enhancing its leadership in the biotechnology sector. Pilant, the CEO of Regenerex Pharma, brings extensive expertise in regenerative medicine, which aligns with Holista’s focus on health solutions and food sciences. His appointment is part of Holista’s strategic plan to innovate in these areas, and his involvement in the company’s recent funding initiative highlights his commitment to its mission.
Holista Colltech Limited has successfully received $1.53 million from Converting Notes and made a final payment of $900,000 to the Australian Securities and Investments Commission, fulfilling obligations under a Federal Court order. These financial developments signify a milestone in Holista’s strategy, emphasizing its commitment to financial stability and regulatory compliance, and allowing the company to focus on advancing its business operations.
Holista Colltech Limited announced an update regarding the timing of the issue of Converting Notes, which is part of a proposed securities issuance. This update is crucial for stakeholders as it may impact the company’s financial strategy and market positioning, reflecting its ongoing efforts to manage capital and investor relations effectively.
Holista Colltech Ltd is facing legal challenges in the U.S. as the United States Court of Appeals dismissed its appeal in a case against The ProImmune Company, LLC, resulting in a damages award of US$2,068,000. Holista plans to defend itself in Australian courts, alleging the judgment was obtained through fraudulent representations by ProImmune. Concurrently, Holista has secured commitments from convertible note holders to raise A$1.54 million, which will be used to settle an ASIC penalty and for working capital.
Holista Colltech Limited has requested a trading halt on its securities pending an announcement regarding new information related to an ongoing legal matter with Proimmune Company LLC in the USA. This trading halt is intended to allow the company time to thoroughly review the information before updating the market, reflecting the company’s commitment to transparency and regulatory compliance.
Holista Colltech Limited reported a significant reduction in net loss by 98% to $84K for FY2024, despite a 6% decline in revenue to $5.6M. The company achieved this through financial recoveries, cost-cutting measures, and strategic partnerships. New product launches, including SKNPRO Collagen and PROBIO-30, and the development of Nano Collagen for wound care, highlight Holista’s focus on innovation and market expansion. The company secured forward orders and is exploring the commercial potential of its patented Nano Collagen, indicating a positive outlook for future growth.
Holista Colltech Limited announced a proposed issue of securities, specifically converting notes, totaling 1,545,100 units. This move is part of a strategic placement or issue aimed at enhancing the company’s financial standing and operational capabilities. The issuance is expected to impact the company’s market positioning by potentially increasing its capital base, thereby supporting its growth initiatives and stakeholder interests.
Holista Colltech Limited has announced the issuance of converting notes totaling approximately AUD1,545,100 to support its growth initiatives and repay outstanding ASIC obligations. This strategic move not only strengthens the company’s financial position but also aligns with its goals of maintaining high corporate governance standards. The involvement of experienced entrepreneurs like Greg Pilant and Tee Kian Heng, who are contributing significantly to the company’s financial base, underscores a robust commitment to Holista’s long-term success and stability.